Nano Spray Drying Technique as a Novel Approach To Formulate

Mar 24, 2016 - Nano Spray Drying Technique as a Novel Approach To Formulate Stable Econazole Nitrate Nanosuspension Formulations for Ocular Use. Amr M...
0 downloads 15 Views 4MB Size
Subscriber access provided by UNIV OF NEBRASKA - LINCOLN

Article

Nano-spray drying technique as a novel approach to formulate stable econazole nitrate nanosuspension formulations for ocular use Amr Maged, Azza Ahmed Mahmoud, and Mahmoud M. Ghorab Mol. Pharmaceutics, Just Accepted Manuscript • DOI: 10.1021/acs.molpharmaceut.6b00167 • Publication Date (Web): 24 Mar 2016 Downloaded from http://pubs.acs.org on March 27, 2016

Just Accepted “Just Accepted” manuscripts have been peer-reviewed and accepted for publication. They are posted online prior to technical editing, formatting for publication and author proofing. The American Chemical Society provides “Just Accepted” as a free service to the research community to expedite the dissemination of scientific material as soon as possible after acceptance. “Just Accepted” manuscripts appear in full in PDF format accompanied by an HTML abstract. “Just Accepted” manuscripts have been fully peer reviewed, but should not be considered the official version of record. They are accessible to all readers and citable by the Digital Object Identifier (DOI®). “Just Accepted” is an optional service offered to authors. Therefore, the “Just Accepted” Web site may not include all articles that will be published in the journal. After a manuscript is technically edited and formatted, it will be removed from the “Just Accepted” Web site and published as an ASAP article. Note that technical editing may introduce minor changes to the manuscript text and/or graphics which could affect content, and all legal disclaimers and ethical guidelines that apply to the journal pertain. ACS cannot be held responsible for errors or consequences arising from the use of information contained in these “Just Accepted” manuscripts.

Molecular Pharmaceutics is published by the American Chemical Society. 1155 Sixteenth Street N.W., Washington, DC 20036 Published by American Chemical Society. Copyright © American Chemical Society. However, no copyright claim is made to original U.S. Government works, or works produced by employees of any Commonwealth realm Crown government in the course of their duties.

Page 1 of 57

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60

Molecular Pharmaceutics

1 2

Nano-spray drying technique as a novel approach to formulate stable econazole nitrate nanosuspension formulations for ocular use

3

Amr Maged 1,*, Azza A. Mahmoud 1,2, Mahmoud M. Ghorab3 1

4 5 6

Department of Pharmaceutics and Pharmaceutical Technology, Faculty of Pharmaceutical Sciences and Pharmaceutical Industries, Future University in Egypt, Cairo, Egypt

7 8

2

9 10

Department of Pharmaceutical Technology, National Research Center, Dokki, Cairo, Egypt 3

Department of Pharmaceutics, Faculty of Pharmacy, Cairo University, Cairo, Egypt

11 12 13

Corresponding author: Amr Maged

14

E-Mail: [email protected]

15

Tel.: +201005849238

16

Address: Department of Pharmaceutics and Pharmaceutical Technology,

17

Future University in Egypt, End of 90th St., Fifth Settlement, New Cairo,

18

Egypt

19 20

Running Head: Nano-spray dried econazole nanosuspension

21 22

ACS Paragon Plus Environment

Molecular Pharmaceutics

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60

Page 2 of 57

23 24

Nano-spray drying technique as a novel approach to formulate stable econazole nitrate nanosuspension formulations for ocular use

25

Amr Maged 1,*, Azza A. Mahmoud 1,2, Mahmoud M. Ghorab3 1

26 27 28 29 30

Department of Pharmaceutics and Pharmaceutical Technology, Faculty of Pharmaceutical Sciences and Pharmaceutical Industries, Future University in Egypt, Cairo, Egypt, 2Department of Pharmaceutical Technology, National Research Center, Dokki, Cairo, Egypt and 3Department of Pharmaceutics, Faculty of Pharmacy, Cairo University, Cairo, Egypt

31

Abstract

32

The effect of using methyl-β-cyclodextrin and hydroxylpropyl-β-cyclodextrin as

33

carriers for econazole nitrate nanoparticles prepared by nano-spray dryer was

34

explored

35

polyvinylpyrrolidone k30, poloxamer 407, Tween 80 and Cremophor EL were

36

used. The nano-spray dried formulations revealed almost spherical particles

37

with an average particle size-values ranging from 121 to 1565 nm and zeta

38

potential-values ranging from -0.8 to -2.5 mV. The yield-values for the obtained

39

formulations reached 80%. The presence of the drug in amorphous state within

40

the nanosuspension matrix system significantly improved drug release from

41

them compared to that for pure drug. Combination of hydroxylpropyl-β-

42

cyclodextrin with Tween 80 achieved important role for preserving the

43

econazole nanosuspension from aggregation during storage for one year at room

44

temperature as well as improving drug release from the nanosuspension. This

45

selected formulation was suspended in chitosan HCl to increase drug release

46

and bioavailability. The in-vivo evaluation on Albino rabbit's eyes demonstrated

47

distinctly superior bioavailability of the selected formulation suspended in

48

chitosan compared to its counterpart formulation suspended in buffer and crude

49

drug suspension due to its mucoadhesive properties and nano-size. The nano-

50

spray dryer could serve as a one step technique towards formulating stable and

51

effective nanosuspensions.

in

this

work.

Stabilizers

namely;

ACS Paragon Plus Environment

polyethylene

oxide,

Page 3 of 57

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60

52

Molecular Pharmaceutics

Keywords: Nano-spray dryer; nanoparticles; eye drops

53 54 55

1. Introduction

56

The eye, the most sensitive and complicated organ in the body, is easily affected

57

by several diseases such as glaucoma, cataract, dry eye and infection 1 . The eye

58

may be infected by fungal contamination through wearing contact lenses,

59

accident, trauma, surgery or rubbing the eye by infected skin 2.

60

Econazole nitrate is classified as antifungal imidazole drug that is used for the

61

treatment of topical fungal infections caused by Candida albicans and Tinea.

62

Econazole nitrate is a water insoluble drug that create complicated barrier for its

63

formulation in ocular drug delivery system 3, 4.

64

Introducing the drug into nano-sized drug delivery system have showed many

65

advantages

66

bioavailability, reducing drug toxicity and increasing drug selectivity to certain

67

organ 5. The ideal ocular drug delivery system should be effective in low dose,

68

provide drug targeting to certain ocular tissues with minimum side effects,

69

prolong drug action by increasing contact time with eye without causing

70

irritation and overcome eye clearance and drainage that cause dose loss 6. The

71

Nano-ocular drug delivery systems include nanoemulsions, liposomes,

72

niosomes, solid lipid nanoparticles (SLN) and nanosuspensions.

73

The nanosuspension drug delivery system can be produced by two technologies,

74

top down and bottom up methods. In top down method, the reduction in drug

75

particle size into smaller particles is done using mechanical forces that may

76

resulting in degradation of drug such as milling and high pressure

77

homogenization 7, 8, while in bottom up method, the drug is dissolved in organic

78

solvent followed by precipitation or drying to get nanoparticles using solvent-

in

improving

aqueous

drug

solubility,

ACS Paragon Plus Environment

increasing

drug

Molecular Pharmaceutics

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60

Page 4 of 57

79

antisolvent or spray drying process. Spray drying process revealed many

80

advantages in increasing drug content and encapsulation efficiency as well as

81

producing particles with uniform size distribution and high drug yield 9.

82

Nano-spray drying process is a new advanced technology to produce

83

nanoparticles. The nano-spray dryer made revolution in spray drying technology

84

by producing formulations with high yield and particle size in the nano-size

85

with very narrow distributions. The nano-spray drying technology depends on

86

spraying the liquid formulations through piezoelectric driven actuator that

87

vibrate a stainless steel mesh (at ultrasonic frequency of 60 kHz) to create tiny

88

aerosol droplets in a smaller size range and with a very narrow distribution

89

compared to that obtained from classical spray dryers. A high voltage is applied

90

between two electrodes during the spray process to produce dried fine solid

91

particles. Those particles are deposited on the inner wall of the electrostatic

92

stainless steel collecting cylinder. At the end of the spray drying process, the

93

dried fine powders are conveniently collected using a scraper 10.

94

The nano-spray dryer was used to prepare gelatine nanoparticles in order to

95

provide a sustained release for amoxicillin. The formulated nanoparticles were

96

able to release the drug over 12 hours in 0.05 M phosphate buffer solution

97

Furthermore, Cyclosporin A and dexamethasone were loaded in poly(d,l-

98

lactide-co-glycolide) (PLGA) nanoparticles using the nano-spray dryer. The

99

obtained nanoparticles showed sustained drug release from 15 to 30 days in

11

.

100

phosphate buffer with pH value of 7.4 12.

101

The aim of this work was to formulate econazole nitrate nanosuspension using

102

spray drying technique aiming to increase its dissolution and bioavailability

103

while avoiding the general stability problems encountered during the storage of

104

the nanoparticle suspension.

ACS Paragon Plus Environment

Page 5 of 57

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60

Molecular Pharmaceutics

105

The resulting nanoparticles were evaluated for their process yield, entrapment

106

efficiency, particle size, zeta potential, in-vitro drug release, morphology and

107

particle size stability during storage at room temperature. Selected econazole

108

nitrate nanoparticles formulation was modified to increase its mucoadhesive

109

properties and was subjected to in-vivo bioavailability study in rabbit's eyes and

110

compared to that of drug suspension.

111 112

2. Materials and methods

113

2.1. Materials

114

Econazole nitrate was a kind gift from Minapharm Pharmaceuticals (Egypt).

115

Poloxamer 407, poly ethylene oxide (molecular weight of 100,000 g/mole) and

116

dialysis tubing cellulose membrane (molecular weight cut-off 14000 g/mole)

117

were purchased from Sigma Aldrich (USA). Methyl-β-cyclodextrin (MβCD)

118

and hydroxylpropyl-β-cyclodextrin (HPβCD) were a kind gift from Roquette

119

(France). Sodium chloride, sodium bicarbonate, calcium chloride dehydrate,

120

potassium chloride, Tween 80 and absolute ethyl alcohol were purchased from

121

El-Nasr Pharmaceutical Chemicals (Egypt). Cremophor EL was obtained from

122

Cisme Chemicals (Italy). Polyvinylpyrrolidone (PVP K 30) was supplied by

123

Morgan Chemical Industries Company (Egypt). Acetonitrile (HPLC grade) was

124

purchased from Research Lab Company (India). Water (HPLC grade) was

125

obtained from Fisher Scientific (UK). Chitosan hydrochloride was a kind gift

126

from Zhejiang Chemicals Import and Export Corporation (China).

127

2.2. Methods

128

2.2.1. Preparation of econazole nitrate nanoparticles

129

The econazole nanoparticles were prepared by nano-spray drying technique.

130

Exactly, 0.2 g of econazole nitrate and specified amounts of carriers and

ACS Paragon Plus Environment

Molecular Pharmaceutics

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60

131

stabilizers (table 1) were dissolved in ethanol (10 ml) followed by spraying

132

through the Buchi® nano-spray dryer B-90 (Büchi Labortechnik, Switzerland).

133

The nano-spray dryer was operated using inert loop B-295 system (Büchi

134

Labortechnik AG, Flawil, Switzerland) operated using nitrogen gas with flow

135

rate of 110 L/min. The spray drying processes were operated at an inlet

136

temperature of 90°C and an outlet temperature of 35°C with a feeding rate of 40

137

mL/hr. The spray mesh with 7.0 µm aperture size was used in our study. The

138

obtained nanoparticles were collected from the wall of the cylindrical collecting

139

electrode of the nano-spray dryer.

140

2.2.2. Evaluation of econazole nitrate nanoparticles

141

2.2.2.1. Determination of nano-spray drying process yield

142

The econazole nitrate nanoparticles collected from nano-spray dryer were

143

weighed and the yield was calculated by the following equation:

Page 6 of 57

% Yield = (Recovered mass / Mass entered in the spray dryer) × 100 144

2.2.2.2. Entrapment efficiency

145

Econazole nitrate nanoparticles were weighed and then dissolved in ethanol to

146

determine the amount of drug in them using Shimadzu 1800 UV (Japan)

147

measured at 271 nm. The entrapment was calculated using the following

148

equation:

% Entrapment efficiency = (Amount of drug in nanoparticles / Weight of nanoparticles) × 100

149

2.2.2.3. Determination of particle size and zeta potential

150

All formulations of econazole nitrate nanoparticles prepared by nano-spray

151

dryer were dispersed in isotonic buffer pH 7.4 and their particle size,

152

polydispersity index (PDI) and zeta potential values were measured using

153

Malvern Nano Zetasizer ZS (UK).

ACS Paragon Plus Environment

Page 7 of 57

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60

Molecular Pharmaceutics

154

2.2.3. Stability of econazole nitrate nanosuspensions

155

All the prepared econazole nitrate formulations suspended in isotonic buffer pH

156

7.4 were stored for six months at room temperature. The stored nanoparticles

157

were characterized for their particle size, PDI and zeta potential values at time

158

intervals of 0, 1, 2, 3, 9, 12, 18, 30, 60, 90, 120, 150 and 180 days.

159

2.2.4. In-vitro drug release studies

160

The prepared econazole nitrate nanoparticles obtained from the nano-spray

161

dryer were suspended in isotonic buffer pH 7.4 and were then tested for drug

162

release by dialysis method in simulating tear fluid of pH of 7.4 containing 10%

163

ethanol. Nanoparticles (equivalent to 2.5 mg of drug) were instilled in dialysis

164

bag (molecular weight cut-off 14000 g/mole) containing 1 ml isotonic buffer

165

with pH value of 7.4 and was secured by two clamps at each end. The dialysis

166

bag was completely soaked in a vessel containing 100 ml of release medium of

167

simulated tear fluid

168

at 34oC (incubator shaker IKA KS 4000, Germany). The vessel was closed to

169

avoid evaporation of the release medium. Samples were taken at specified time

170

intervals. The samples were measured spectrophotometrically at 221.5 nm using

171

Shimadzu 1800 UV (Japan). Release efficiency (RE) was calculated using the

172

following equation 14: RE = (#% y × dt / y100 × t) × 100

173

where, y is the amount of drug released at time t and y100 donates 100% release.

174

2.2.5. Differential scanning calorimetry (DSC)

175

The formulation which gave best drug release and stability was subjected to

176

DSC thermogram analysis. DSC analysis was used to study the crystallinity of

177

the drug in the selected formulation and physical mixture of the formulation.

178

DSC studies were carried out on econazole nitrate powder, the carrier (HPβCD),

179

selected formulation and its physical mixture using differential scanning

13

with shaking rate of 200 stroke per min and maintaining

$

ACS Paragon Plus Environment

Molecular Pharmaceutics

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60

180

calorimeter (DSC-50, Shimadzu, Japan). The procedure involved heating an

181

accurately weighed of samples (5 mg) encapsulated in aluminum pan at

182

scanning rate of 10⁰C/min and over predetermined temperature range from

183

30⁰C to 400⁰C. Dry nitrogen gas was used as carrier gas with flow rate of 25

184

mL/min.

185

2.2.6. X-ray diffraction studies (XRD)

186

X-ray diffraction patterns of econazole nitrate, carrier and selected formulation

187

were obtained. The samples were irradiated with Ni filtered Cu Kα radiation

188

with an operating voltage of 45kV and current of 40 mA using Diano X-ray

189

diffractometer apparatus (USA). The employed scanning rate was 2⁰/min over

190

diffraction angle (2θ) range of 3-70⁰.

191

2.2.7. Scanning electron microscopy (SEM)

192

The shape of selected econazole nanoparticles formulated by spray dryer was

193

evaluated using a scanning electron microscope (Quanta FEG250, USA). The

194

nanoparticles were coated with gold and were examined at 10 kV.

195

2.2.8. Transmission electron microscopy (TEM)

196

Selected formulations were examined by transmission electron microscope

197

(JEM-HR-2100, Jeol, Japan), where, the samples were stained by 2%

198

phosphotungstic acid solution and then dried at room temperature to be

199

examined at 160 kV.

200

2.2.9. Viscosity determination

201

The viscosity of selected nanosuspension formulations was measured by

202

Brookfield cone and plate viscometer using spindle CS-40 (DV3T, USA). The

203

required volume that was placed between cone and plate was 3 ml and

204

temperature was adjusted at room temperature.

ACS Paragon Plus Environment

Page 8 of 57

Page 9 of 57

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60

Molecular Pharmaceutics

205

2.2.10. Mucoadhesion study

206

Selected formulations suspended in isotonic buffer pH 7.4 or in 0.1% chitosan

207

HCl solution were mixed with equal volume of mucin solution (0.4 mg/ml) by

208

vortex for 1 min, then the resulted mixtures were evaluated for their zeta

209

potential and particle size values 15.

210

2.2.11. Ocular irritation study

211

The ocular irritation study was performed on 12 Albino rabbits which were

212

divided into two groups, each group consisted of 6 rabbits. The first group

213

received the selected econazole nitrate nanoparticles that were dispersed in

214

isotonic buffer 7.4 (EH-TW2) on the right eye and the second group received

215

the selected nanoparticles that were dispersed in 0.1 % chitosan HCl solution

216

(EH-TW2C), while the left eye worked as a control for both groups.

217

The administration of 50 µL of econazole formulation into rabbit's eyes was

218

repeated three times every 2.5 hour per day for the first three days and once on

219

the fourth day 16. According to Draize test the rabbit's eye was tested after 1 and

220

24 hour from last instillation of the formulation

221

adverse reactions and irritation of cornea, conjunctiva, eyelids, anterior chamber

222

and iris was performed. The evaluation criteria were classified as follows: no

223

irritation (0 – 3.9), slight irritation (4 – 8.9), moderate irritation (9 – 12.9) and

224

high irritation (13 – 16) 18.

225

2.2.12. In-vivo evaluation of selected econazole nitrate nanoparticles

226

2.2.12.1. Study design

227

The study was performed on three formulations containing drug concentration

228

of 125 µg/ml; prepared nanoparticles suspended in 0.1% chitosan HCl or in

229

isotonic buffer pH 7.4 as well as drug suspension. The tested formulations were

230

sterilized with gamma radiation using a dose of 10 kGy. This study was

17

. The evaluation for any

ACS Paragon Plus Environment

Molecular Pharmaceutics

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60

231

approved by the Research Ethics Committee, Faculty of Pharmacy, Cairo

232

University, Cairo, Egypt (No: PI 1149). Eighteen healthy Albino rabbits

233

(weighing 1.5-2 kg) were randomly divided into three groups, each containing

234

six rabbits. A parallel group design was applied, so that each group received

235

single ocular dose of tested formulation.

236

2.2.12.2. Tear film sampling

237

The rabbit's eyes received 50 µL of tested formulation that was instilled in the

238

conjunctival sac. Samples of tear films were collected by placing two sterile

239

filter paper discs (6 mm in diameter) under the lower eyelid of the rabbit's eye

240

for only 1 min at different time points as follows: zero (pre-dose), 0.5, 1, 2, 3, 4,

241

5, 6, 7 and 8 hours. Full care was taken during sampling to avoid the irritation

242

of the eyelid margin. The collected discs were immersed in 50 µL of acetonitrile

243

and stored in Eppendorfs at −20◦C until being analyzed. Depending on the in-

244

vivo study design to assess the pharmacokinetic profiles of econazole nitrate, its

245

total amount in the collected tears was displayed as a function of time, and the

246

following pharmacokinetic parameters were calculated (Cmax, Tmax, AUC(0-24hr),

247

AUC(0-∞), AUMC(0-24hr), AUMC(0-∞) and MRT).

248

2.2.12.3. Chromatographic conditions

249

The concentration of econazole nitrate was analyzed in rabbit's tears applying a

250

validated high performance liquid chromatography method described by Ng et

251

al

252

detector and isocratic pump (LC-20AT, Shimadzu, Japan) was used. A C18

253

reversed phase analytical column (250 mm × 4.6 I.D. mm, particle size 5 µm,

254

Berlin, Germany) was used.

255

The filtered and degassed mobile phase consisted of acetonitrile and 12 mM

256

sodium acetate buffer with ratio of 75:25 v/v and its pH value was 8.5. The flow

19

. A high performance liquid chromatography system with an ultraviolet

ACS Paragon Plus Environment

Page 10 of 57

Page 11 of 57

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60

Molecular Pharmaceutics

257

rate of the mobile phase was set to 1.5 ml/min and the drug was detected at 220

258

nm.

259

2.2.13. Statistical analysis

260

The data were collected and were expressed as mean values ± SD. The data

261

were subjected to statistical analysis by applying two-way analysis of variance

262

(ANOVA). Statistical analysis was performed using SPSS® software, USA. The

263

difference between values was considered to be significant at p